AstraZeneca and Merck & Co. have developed a first-of-its-kind drug that slows the return of particularly aggressive hereditary form of breast cancer. The recent study done on 1836 patients has been presented at the virtual meeting of American Society of Oncology. The findings of the research were published in the New England Journal of Medicine on Thursday.
The participants in the study received the drug called Lynparza or placebo for a year of adjuvant treatment which is after surgery to remove a tumor and taking standard drugs for cancer such as radiation, chemotherapy, or hormone therapy. All participants inherited a mutation to either gene BRCA1 or BRCA2. These participants were considered at high risk of redeveloping cancer because of the size of tumors or other reasons.
During this study researchers found Lynparza reduced risk of cancer recurrence or death by 42% compared to placebo. The researchers also observed that patients who were given Lynparza also had 43% lower risk of developing more lethal distant tumors.
Read More News: Click Here